Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.
More than a year after CNN's exposé about Avanir's Neudexta marketing, the company is nearing a settlement with U.S. officials.
It seems logical: pharmas teaching doctors' staff how to handle patients using their drugs. But a slew of companies are discovering it's not so simple.
Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.
After Michael Avenatti leveled allegations of "suspicious" payments, Novartis says it paid Michael Cohen $1.2 million for unused consulting services.
A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.
Purdue made a splash with its plans to stop marketing opioids this week, but Endo, Teva, Allergan and J&J had already quit.